Dasatinib
- Generic Name
- Dasatinib
- Brand Names
- Sprycel
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26ClN7O2S
- CAS Number
- 302962-49-8
- Unique Ingredient Identifier
- X78UG0A0RN
- Background
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...
- Indication
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
- Conditions
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 404
- Registration Number
- NCT04971226
- Locations
- 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom
🇺🇸Texas Oncology Austin, Dallas, Texas, United States
🇺🇸Texas Oncology Texas Onc - Amarillo, Dallas, Texas, United States
The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients
- Conditions
- Interventions
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Shenzhen Second People's Hospital
- Target Recruit Count
- 118
- Registration Number
- NCT04933526
- Locations
- 🇨🇳
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- St Vincent's Hospital, Sydney
- Target Recruit Count
- 22
- Registration Number
- NCT04925648
- Locations
- 🇦🇺
Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Asciminib Roll-over Study
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 347
- Registration Number
- NCT04877522
- Locations
- 🇺🇸
Michigan Med University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Memorial Sloan Kettering, New York, New York, United States
🇺🇸Oregon Health Sciences University, Portland, Oregon, United States
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04872790
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Registration Number
- NCT04845035
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT04835584
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇮🇹Azienda Ospedaliero - Universitaria Mater Domini, Catanzaro, Italy
🇮🇹Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 51
- Registration Number
- NCT04838041
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸The Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Dasatinib for the Treatment of Moderate and Severe COVID-19
- Conditions
- Interventions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- University of Southern California
- Registration Number
- NCT04830735
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
ALSENLITE: Senolytics for Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT04785300
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.